(NASDAQ: NERV) Minerva Neurosciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.43%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.27%.
Minerva Neurosciences's earnings in 2026 is -$395,169,043.On average, 5 Wall Street analysts forecast NERV's earnings for 2026 to be -$24,351,255, with the lowest NERV earnings forecast at -$23,396,304, and the highest NERV earnings forecast at -$25,067,468. On average, 5 Wall Street analysts forecast NERV's earnings for 2027 to be -$26,542,868, with the lowest NERV earnings forecast at -$31,351,047, and the highest NERV earnings forecast at -$21,056,674.
In 2028, NERV is forecast to generate -$27,980,070 in earnings, with the lowest earnings forecast at -$46,744,860 and the highest earnings forecast at -$7,520,241.